The realities of clonazepam discontinuation.
Freeman
S
S
Harvard Longwood, Boston, Massachussetts 02215, USA.
D000525:Alprazolam / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001008:Anxiety Disorders / Q000188:drug therapy*; D001569:Benzodiazepines / Q000009:adverse effects / Q000493:pharmacokinetics; D002998:Clonazepam / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D018757:GABA Modulators / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D006207:Half-Life; D006801:Humans; D001523:Mental Disorders / Q000139:chemically induced; D010349:Patient Compliance; D012640:Seizures / Q000139:chemically induced; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control
D018757:GABA Modulators; D001569:Benzodiazepines; D002998:Clonazepam; D000525:Alprazolam